Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981595 | 0.93 | MEN1 (0.64) | KMT2AMEN1POLBMCHR1SMN1; SMN2 | |
| SCHEMBL14263123 | 0.82 | POLB (0.54) | KMT2AMEN1POLBMCHR1SMN1; SMN2 | |
| SCHEMBL30523668 | 0.80 | HPGD (0.48) | KMT2AMEN1POLBMCHR1SMN1; SMN2 | |
| SCHEMBL4975820 | 0.80 | EPHX1 (0.52) | KMT2AMEN1POLBMCHR1SMN1; SMN2 | |
| SCHEMBL4981899 | 0.80 | MCHR1 (0.51) | KMT2AMEN1POLBMCHR1SMN1; SMN2 | |
| SCHEMBL4978994 | 0.79 | SMN1; SMN2 (0.72) | KMT2AMEN1POLBMCHR1SMN1; SMN2 | |
| SCHEMBL4980687 | 0.79 | HPGD (0.52) | KMT2AMEN1POLBMCHR1SMN1; SMN2 | |
| SCHEMBL5470035 | 0.78 | MEN1 (0.61) | KMT2AMEN1POLBSMN1; SMN2CA1 | |
| SCHEMBL4982545 | 0.78 | MCHR1 (0.66) | MCHR1SMN1; SMN2ALDH1A1HPGDMAPT | |
| SCHEMBL4981939 | 0.78 | EPHX1 (0.71) | KMT2AMEN1MCHR1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | KMT2A 395/4885MEN1 3498/4885POLB 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.